Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol 2021;17(3):150–61. https://doi.org/10.1038/s41574-020-00443-4

McCarthy MM, Grey M. Type 1 Diabetes self-management from emerging adulthood through older adulthood. Diabetes Care 2018; 41(8):1608–14. https://doi.org/10.2337/dc17-2597

Moström P, Ahlén E, Imberg H, Hansson PO, Lind M. Adherence of self-monitoring of blood glucose in persons with type 1 diabetes in Sweden. BMJ Open Diabetes Res Care 2017;5(1):e000342. https://doi.org/10.1136/bmjdrc-2016-000342

Vincze G, Barner JC, Lopez D. Factors associated with adherence to self-monitoring of blood glucose among persons with diabetes. Diabetes Educ 2004;30(1):112–25. https://doi.org/10.1177/ 014572170403000119

Hirsch I. Introduction: history of glucose monitoring. ADA Clinical Compendia 2018 Aug;1–1. https://doi.org/10.2337/db20181-1

Leelarathna L, Wilmot EG. Flash forward: a review of flash glucose monitoring. Diabetic Medicine 2018;35(4):472–82. https://doi.org/10.1111/dme.13584

Thabit H, Bally L, Hovorka R. Available at a flash: a new way to check glucose. Lancet 2016;388(10057):2213–4. https://doi.org/10.1016/S0140-6736(16)31582-3

freestyle libre 2 can now work as a real-time continuous glucose monitor. accessed on 2300 . 2023. https://www.diabetes.org.uk/about_us/news/freestyle-libre-2-can-now-work-real-time-continuous-glucose-monitor#:~:text=On%203%20August%2C%20Abbott%20announced,FreeStyle%20Libre%202%20sensor%20users.

Reiterer F, Polterauer P, Schoemaker M, et al. Significance and reliability of MARD for the accuracy of CGM systems. J Diabetes Sci Technol 2017;11(1):59–67. https://doi.org/10.1177/1932296816662047

Kovatchev BP, Patek SD, Ortiz EA, Breton MD. Assessing sensor accuracy for non-adjunct use of continuous glucose monitoring. Diabetes Technol Ther 2015;17(3):177-86. https://doi.org/10.1089/dia.2014.0272

Obermaier K, Schmelzeisen-Redeker G, Schoemaker M, et al. Performance evaluations of continuous glucose monitoring systems: precision absolute relative deviation is part of the assessment. J Diabetes Sci Technol 2013;7(4):824–32. https://doi.org/10.1177/193229681300700404

Diabetes Nurse Forum CGM comparison Chart Version 5, 2023. https://www.diabetesspecialistnurseforumuk.co.uk/whats-new

The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359(14):1464–76. https://doi.org/10.1056/NEJMoa0805017

Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycaemic control in adults with type 1 diabetes treated with multiple daily insulin injections. JAMA 2017; 317(4):379. https://doi.org/10.1001/jama.201619976

Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycaemic control in adults with type 1 diabetes using insulin injections. JAMA 2017;317(4):371-8. https://doi.org/10.1001/jama.2016.19975

Pratley RE, Kanapka LG, Rickels MR, et al. Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes. JAMA 2020;323(23):2397-2406. https://doi.org/10.1001/jama.2020.6928

Laffel LM, Kanapka LG, Beck RW, et al. Effect of continuous glucose monitoring on glycaemic control in adolescents and young adults with type 1 diabetes. JAMA 2020;323(23):2388-96. https://doi.org/10.1001/jama.2020.6940

Thabit H, Prabhu JN, Mubita W, et al. Use of factory-calibrated real- time continuous glucose monitoring improves time in target and HbA1c in a multiethnic cohort of adolescents and young adults with type 1 diabetes: the MILLENNIALS study. Diabetes Care 2020; 43(10):2537–43. https://doi.org/10.2337/dc20-0736

Phillip M, Nimri R, Bergenstal RM, et al. Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. Endocr Rev 2023;44(2):254–80. https://doi.org/10.1210/endrev/bnac022

Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, Krӧger J, Weitgasser R, Bolinder J. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. Diabetologia 2018;61(3):539–50. https://doi.org/10.1007/s00125-017-4527-5

Elliott RA, Rogers G, Evans ML, et al. Estimating the cost‐effectiveness of intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in England. Diabetic Medicine 2024;41(3):e15232. https://doi.org/10.1111/dme.15232

Leelarathna L, Evans ML, Neupane S, et al. Intermittently scanned continuous glucose monitoring for type 1 diabetes. N Engl J Med 2022;387(16):1477–87. https://doi.org/10.1056/NEJMoa2205650

Visser MM, Charleer S, Fieuws S, et al. Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial. Lancet Diabetes Endocrinol 2023; 11(2):96–108. https://doi.org/10.1016/S2213-8587(22)00352-7

Shah N, Deshmukh H, Wilmot EG, et al. The long‐term impact of glucose monitoring with the FreeStyle Libre on glycaemic control and hypoglycaemia awareness in people with type 1 diabetes: insights from the Association of British Clinical Diabetologists national audit. Diabetic Medicine 2023;40(6):e15070. https://doi.org/10.1111/dme.15070

Charleer S, Mathieu C, Nobels F, et al. Effect of continuous glucose monitoring on glycaemic control, acute admissions, and quality of life: a real-world study. J Clin Endocrinol Metab 2018;103(3):1224–32. https://doi.org/10.1210/jc.2017-02498

Leelarathna L, Choudhary P, Wilmot EG, et al. Hybrid closed‐loop therapy: where are we in 2021? Diabetes Obes Metab 2021; 23(3):655–60. https://doi.org/10.1111/dom.14273

Diabetes Specialist Nurse Forum UK. Version 5.0. Diabetes Specialist Nurse Forum comparison chart of Hybrid Closed Loop systems. https://www.diabetesspecialistnurseforumuk.co.uk/whats-new

Braune K, Lal RA, Petruželková L, et al. Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals. Lancet Diabetes Endocrinol 2022;10(1):58–74. https://doi.org/10.1016/S2213-8587(21)00267-9

Burnside MJ, Lewis DM, Crocket HR, et al. Open-source automated insulin delivery in type 1 diabetes. N Engl J Med 2022;387(10):869–81. https://doi.org/10.1056/NEJMoa2203913

Ware J, Boughton CK, Allen JM, et al. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. Lancet Digit Health 2022;4(4):e245–55. https://doi.org/10.1016/S2589-7500(22)00020-6

Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-loop insulin delivery during pregnancy in women with type 1 diabetes. N Engl J Med 2016;375(7):644–54. https://doi.org/10.1056/NEJMoa1602494

Lee TTM, Collett C, Bergford S, et al. Automated insulin delivery in women with pregnancy complicated by type 1 diabetes. N Engl J Med 2023;389(17):1566–78. https://doi.org/10.1056/NEJMoa2303911

Tauschmann M, Thabit H, Bally L, et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet 2018;392(10155):1321–9. https://doi.org/10.1016/S01406736(18)31947-0

Bergenstal RM, Nimri R, Beck RW, et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet 2021; 397(10270):208–19. https://doi.org/10.1016/S0140-6736(20)32514-9

Choudhary P, Kolassa R, Keuthage W, et al. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. Lancet Diabetes Endocrinol 2022;10(10):720–31. https://doi.org/10.1016/S2213-8587(22)00212-1

Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 2019;381(18):1707–17. https://doi.org/10.1056/NEJMoa1907863

Breton MD, Kovatchev BP. One year real-world use of the Control- IQ advanced hybrid closed-loop technology. Diabetes Technol Ther 2021;23(9):601–8. https://doi.org/10.1089/dia.20210097

Brown SA, Forlenza GP, Bode BW, et al. Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycaemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care 2021;44(7):1630–40. https://doi.org/10.2337/dc21-0172

Crabtree TSJ, Griffin TP, Yap YW, et al. Hybrid closed-loop therapy in adults with type 1 diabetes and above-target HbA1c: a real-world observational study. Diabetes Care 2023;46(10):1831–8. https://doi.org/10.2337/dc23-0635

NHS runs world-first test into ‘sci-fi like’ artificial pancreases, 2022.

Sy SL, Munshi MM, Toschi E. Can smart pens help improve diabetes management? J Diabetes Sci Technol 2020;16(3):628–34. https://doi.org/10.1177/1932296820965600

Munshi MN, Slyne C, Greenberg JM, et al. Nonadherence to insulin therapy detected by Bluetooth-enabled pen cap Is associated with poor glycaemic control. Diabetes Care 2019;42(6):1129–31. https://doi.org/10.2337/dc18-1631

Gomez-Peralta F, Abreu C, Fernández-Rubio E, et al. Efficacy of a connected insulin pen cap in people with noncontrolled type 1 diabetes: a multicenter randomized clinical trial. Diabetes Care 2023;46(1):206–08. https://doi.org/10.2337/dc22-0525

Speight J, Choudhary P, Wilmot EG, et al. Impact of glycaemic technologies on quality of life and related outcomes in adults with type 1 diabetes: a narrative review. Diabetic Medicine 2023; 40(1):e14944. https://doi.org/10.1111/dme.14944

https://www.diabeteseducator.org/danatech/glucose-monitoring/continuous-glucose-monitors-(cgm)/cgm-101/pros-cons-of-cgm#:~:text=Potential%20DISADVANTAGES. accessed on 10/11/2023 at 1400. WEIGHING CGM PROS AND CONS.

Andrew E, Crabtree TSJ, Richardson P, et al. Poster abstracts: Retinopathy outcomes associated with hybrid-closed loop therapy in the NHS England pilot at the University Hospitals of Derby and Burton NHS Trust (UHDB): single centre report from the Association of British Clinical Diabetologists (ABCD) audit. Diabetic Medicine 2023;40(S1):P256. https://doi.org/1111/dme.15048

Type 1 diabetes in adults: diagnosis and management NICE guideline [NG17]. Published 26 August 2015. Last updated: 17 August 2022. Continuous glucose monitoring. https://www.nice.org.uk/guidance/ng17/chapter/Recommendations#blood-glucose-management.

NICE Guidelines. Technology appraisal guidance [TA943]. Last seen at 17/01/2024 @ 1720. 2023. Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. https://doi.org/10.2337/dc19-2267

Wilson LM, Jacobs PG, Ram Esey KL, et al. Dual-hormone closed- loop system using a liquid stable glucagon formulation versus insulin-only closed-loop system compared with a predictive low glucose suspend system: an open-label, outpatient, single-center, crossover, randomized controlled trial. Diabetes Care 2020; 43(11):2721–9. https://doi.org/10.237/dc19-2267

Castellanos LE, Balliro CA, Sherwood JS, et al. Performance of the insulin-only iLet bionic pancreas and the bihormonal iLet using dasiglucagon in adults with type 1 diabetes in a home-use setting. Diabetes Care 2021;44(6):e118–20. https://doi.org/10.2337/dc20-1086

Xiao Z, Tan X, Chen X, et al. An implantable RFID sensor tag toward continuous glucose monitoring. IEEE J Biomed Health Informatics 2015;19:910–19. https://doi.org/10.1109/JBHI.2015.2415836